Clinical Scorecard: Exploring Gene-Environment Interactions in Inflammatory Bowel Disease: A Comprehensive Review of Human Epidemiological Research
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD), including Crohn’s disease (CD) and Ulcerative colitis (UC)
Key Mechanisms
Complex interactions between genetic variants and environmental exposures influencing IBD risk
Target Population
Individuals at risk for or diagnosed with IBD across diverse ancestries, including European and East Asian populations
Care Setting
Research and clinical settings focusing on genetic epidemiology and personalized medicine for IBD
Key Highlights
NOD2-smoking interaction, particularly variant rs2066847, is the most frequently studied gene-environment interaction affecting Crohn’s disease risk.
Gene-environment interactions extend to other IBD risk genes (ATG16L1, IL23R, CALM3), detoxification genes (GSTP1, HMOX1), and smoking-associated genes (CHRNA3, CHRNA5, PPP1R3C, BDNF).
Gene-diet interactions involve multiple nutritional factors such as fatty acids, selenium, potassium, alcohol, heme iron, and vitamin D interacting with specific genetic loci.
Guideline-Based Recommendations
Diagnosis
Consider genetic testing for known IBD-associated loci (e.g., NOD2, TNFSF15) to assess individual risk profiles.
Evaluate environmental exposures including smoking status and dietary habits as part of comprehensive IBD risk assessment.
Management
Incorporate personalized lifestyle and dietary modifications based on individual genetic backgrounds to potentially reduce IBD risk or severity.
Encourage smoking cessation especially in individuals carrying risk variants such as NOD2 rs2066847.
Monitoring & Follow-up
Monitor changes in environmental exposures and their potential impact on disease progression in genetically susceptible individuals.
Follow emerging evidence from genome-wide environment interaction studies to refine personalized management strategies.
Risks
Recognize that environmental risk factors may have differential effects depending on the patient’s genotype, influencing disease susceptibility and progression.
Be aware of population-specific genetic differences that may affect gene-environment interactions and IBD risk.
Patient & Prescribing Data
Patients with IBD or at risk for IBD, including diverse ethnic backgrounds with variable genetic allele frequencies.
Genotype-based nutrition and lifestyle interventions hold promise but require further clinical trials to establish efficacy and guidelines.
Clinical Best Practices
Integrate genetic and environmental risk factor assessments in IBD patient evaluations.
Promote smoking cessation and tailored dietary recommendations based on genetic susceptibility.
Support participation in genotype-based clinical trials to advance personalized IBD management.
Consider ancestry-specific genetic differences when interpreting risk and planning interventions.
by Jingjing Bai, Dianne Gelien Bouwknegt, Rinse Karel Weersma, Gerard Dijkstra, Kimberley Wilhelmina Johanna van der Sloot, Eleonora Anna Margaretha Festen
